 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...132133134135136137138139140141142143144» |
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: LEOPARD II: Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer (clinicaltrials.gov) - Feb 6, 2013
P2, N=134, Recruiting, Sponsor: University of Schleswig-Holstein
- Erbitux (cetuximab) / Eli Lilly, Zelboraf (vemurafenib) / Roche
New P1 trial, Combination therapy, Surgery, Metastases: Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery (clinicaltrials.gov) - Feb 6, 2013
P1, N=77, Recruiting, Sponsor: M.D. Anderson Cancer Center
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer (clinicaltrials.gov) - Feb 6, 2013
P2, N=74, Completed, Sponsor: Eastern Cooperative Oncology Group
Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, brivanib alaninate (BMS-582664) / ZAI Lab
P1/2 data, Trial initiation date, Combination therapy, Metastases: Phase I/II Combination With Irinotecan- Erbitux (clinicaltrials.gov) - Feb 5, 2013
P1/2, N=38, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Initiation date: Jun 2001 --> May 2008
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, brivanib alaninate (BMS-582664) / ZAI Lab
P1/2 data, Enrollment change, Combination therapy, Metastases: Phase I/II Combination With Irinotecan- Erbitux (clinicaltrials.gov) - Feb 5, 2013
P1/2, N=38, Completed, Sponsor: Bristol-Myers Squibb
Initiation date: Jun 2001 --> May 2008 N=114 --> 38
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, brivanib alaninate (BMS-582664) / ZAI Lab
Trial completion, P1/2 data, Combination therapy, Metastases: Phase I/II Combination With Irinotecan- Erbitux (clinicaltrials.gov) - Feb 5, 2013
P1/2, N=38, Completed, Sponsor: Bristol-Myers Squibb
N=114 --> 38 Active, not recruiting --> Completed
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases: A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer (clinicaltrials.gov) - Feb 5, 2013
P2, N=66, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Combination therapy, Metastases: Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 31, 2013
P2, N=36, Completed, Sponsor: SCRI Development Innovations, LLC
Active, not recruiting --> Completed N=70 --> 36
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases: Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC (clinicaltrials.gov) - Jan 31, 2013
P2, N=601, Completed, Sponsor: Accelerated Community Oncology Research Network
N=70 --> 36 Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: Reduced-intensity Therapy for Advanced Oropharyngeal Cancer in Non-smoking Human Papilloma Virus (HPV)-16 Positive Patients (clinicaltrials.gov) - Jan 29, 2013
P2, N=36, Active, not recruiting, Sponsor: University of Michigan Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer (clinicaltrials.gov) - Jan 28, 2013
P2, N=26, Completed, Sponsor: Fox Chase Cancer Center
Recruiting --> Active, not recruiting N=34 --> 26
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer (clinicaltrials.gov) - Jan 28, 2013
P2, N=26, Completed, Sponsor: Fox Chase Cancer Center
N=34 --> 26 Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, buparlisib (AN2025) / Novartis, Adlai Nortye
Enrollment open, Monotherapy, Metastases: PIK-ORL: Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive (clinicaltrials.gov) - Jan 27, 2013
P2, N=70, Recruiting, Sponsor: Centre Leon Berard
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| napabucasin (BBI608) / Sumitomo Pharma
New P2 trial, Metastases: A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Jan 24, 2013
P2, N=66, Recruiting, Sponsor: Boston Biomedical, Inc
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Koselugo (selumetinib) / Merck (MSD), AstraZeneca
Trial initiation date, Combination therapy: Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors (clinicaltrials.gov) - Jan 23, 2013
P1, N=33, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Initiation date: Oct 2010 --> Oct 2012
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: Randomised Phase II Pilot Studiy: Induction Chemotherapy with Docetaxel, Cisplatin und Cetuximab versus Docetaxel, Cisplatin und 5 FU followed by Radiotherapy with Cetuximab for locally advanced or not resectable Carcinoma of the Head and Neck Randomisierte Phase II Pilot Studie: Induktionstherapie mit Docetaxel, Cisplatin und Cetuximab versus Docetaxel, Cisplatin und 5 FU gefolgt von Radioimmuntherapie mit Cetuximab bei lokal fortgeschrittenen oder inoperablen HNO Tumoren (EUDRACT) - Jan 21, 2013
P2, N=100, Ongoing, Sponsor: AGMT
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, abituzumab (EMD 525797) / EMD Serono, SFJ Pharma
Enrollment closed, Combination therapy, Metastases: POSEIDON: EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 21, 2013
P1/2, N=228, Active, not recruiting, Sponsor: Merck KGaA
Initiation date: Oct 2010 --> Oct 2012 Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Tomudex (raltitrexed) / Pfizer, AstraZeneca
Enrollment open, Metastases: Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic (clinicaltrials.gov) - Jan 20, 2013
P2, N=80, Recruiting, Sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases: Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC (clinicaltrials.gov) - Jan 15, 2013
P2, N=40, Completed, Sponsor: University of Pittsburgh
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, brivanib alaninate (BMS-582664) / ZAI Lab
Trial completion, Combination therapy, Metastases: Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 9, 2013
P3, N=750, Completed, Sponsor: NCIC Clinical Trials Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination, Combination therapy, Metastases: Combination Chemotherapy, Cetuximab and Radiation for Patients With Localized Gastric Cancer (clinicaltrials.gov) - Jan 7, 2013
P1/2, N=1, Terminated, Sponsor: Dr Anna Dorothea Wagner
Active, not recruiting --> Completed Recruiting --> Terminated; Outcome of EXPAND study (no benefit from adding cetuximab to the first-line chemotherapy in advanced gastric cancer in the overall patient population)
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Combination therapy, Metastases: Combination Chemotherapy, Cetuximab and Radiation for Patients With Localized Gastric Cancer (clinicaltrials.gov) - Jan 7, 2013
P1/2, N=1, Terminated, Sponsor: Dr Anna Dorothea Wagner
Recruiting --> Terminated; Outcome of EXPAND study (no benefit from adding cetuximab to the first-line chemotherapy in advanced gastric cancer in the overall patient population) N=18 --> 1
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442) (clinicaltrials.gov) - Jan 7, 2013
P2, N=43, Completed, Sponsor: Department of Radiation Oncology
N=18 --> 1 N=60 --> 43
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (clinicaltrials.gov) - Jan 7, 2013
P1/2, N=43, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=60 --> 43 Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination, Surgery, Metastases: Cetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Jan 6, 2013
P2, N=47, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated; Recruitment was suspended prematurely for safety concerns and closed after IDMC review
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P1/2 trial, Surgery, Metastases, Post-surgery: CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment in Locally Advanced Tongue Cancer ; A NEW PARADIGM OF TREATMENT (clinicaltrials.gov) - Jan 2, 2013
P1/2, N=25, Not yet recruiting, Sponsor: Rabin Medical Center
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Lynparza (olaparib) / Merck (MSD), AstraZeneca
New P1 trial, Combination therapy, Metastases: Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History (clinicaltrials.gov) - Dec 30, 2012
P1, N=24, Recruiting, Sponsor: University of Colorado, Denver
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, SIR-Spheres (yttrium-90 microspheres) / SIRTeX Medical
Trial withdrawal, Metastases: Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver (clinicaltrials.gov) - Dec 27, 2012
P2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Terminated; Recruitment was suspended prematurely for safety concerns and closed after IDMC review Terminated --> Withdrawn
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer (clinicaltrials.gov) - Dec 27, 2012
P2, N=6, Terminated, Sponsor: University of Kansas
Terminated --> Withdrawn N=38 --> 6
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Compliance, Metastases: PREMIUM, Observational Study (clinicaltrials.gov) - Dec 25, 2012
P=N/A, N=500, Active, not recruiting, Sponsor: Dr.Laurent Mineur
- ||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Combination therapy, Metastases: TAILOR: A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients (clinicaltrials.gov) - Dec 19, 2012
P3, N=443, Active, not recruiting, Sponsor: Merck KGaA
N=38 --> 6 N=360 --> 443
- ||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Combination therapy, Metastases: TAILOR: A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients (clinicaltrials.gov) - Dec 19, 2012
P3, N=443, Active, not recruiting, Sponsor: Merck KGaA
N=360 --> 443 Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, FDG PET, Metastases: Determine Tumor Response Using Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET)/Computed Tomography (CT) Before and After Cetuximab in Patients With Head and Neck Cancer (clinicaltrials.gov) - Dec 19, 2012
P2, N=42, Active, not recruiting, Sponsor: Washington University School of Medicine
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Surgery: SWOG-ECOG-E2204: Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery (clinicaltrials.gov) - Dec 19, 2012
P2, N=137, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX) (clinicaltrials.gov) - Dec 19, 2012
P3, N=1861, Completed, Sponsor: Merck KGaA
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Enrollment open, Metastases: Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 18, 2012
P1/2, N=124, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change: Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer (clinicaltrials.gov) - Dec 16, 2012
P2/3, N=259, Active, not recruiting, Sponsor: Wales Cancer Trials Unit
Not yet recruiting --> Recruiting N=420 --> 259
- |||| Piqray (alpelisib) / Novartis
Enrollment open, Combination therapy, Metastases: A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Dec 16, 2012
P2, N=186, Recruiting, Sponsor: Novartis Pharmaceuticals
N=420 --> 259 Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed: Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer (clinicaltrials.gov) - Dec 16, 2012
P2/3, N=259, Active, not recruiting, Sponsor: Wales Cancer Trials Unit
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment closed, Combination therapy: Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma (clinicaltrials.gov) - Dec 15, 2012
P3, N=150, Active, not recruiting, Sponsor: Trans-Tasman Radiation Oncology Group (TROG)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
Trial termination, Metastases: Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Dec 12, 2012
P1/2, N=11, Terminated, Sponsor: University of Tennessee Cancer Institute
Recruiting --> Active, not recruiting Recruiting --> Terminated
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
Enrollment change, Metastases: Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Dec 12, 2012
P1/2, N=11, Terminated, Sponsor: University of Tennessee Cancer Institute
Recruiting --> Terminated N=56 --> 11
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change: ERBIFORT: Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung (clinicaltrials.gov) - Dec 9, 2012
P2, N=24, Completed, Sponsor: National Cancer Institute, France
N=56 --> 11 N=36 --> 24
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: ERBIFORT: Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung (clinicaltrials.gov) - Dec 9, 2012
P2, N=24, Completed, Sponsor: National Cancer Institute, France
N=36 --> 24 Recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer (clinicaltrials.gov) - Dec 9, 2012
P2, N=109, Completed, Sponsor: Cancer and Leukemia Group B
Recruiting --> Completed Active, not recruiting --> Completed
- |||| E7820 / Eisai
Biomarker, Trial completion, Metastases: A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors (clinicaltrials.gov) - Dec 5, 2012
P2, N=99, Completed, Sponsor: Eisai Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Halaven (eribulin mesylate) / Eisai, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P1/2 trial, Metastases: A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer (clinicaltrials.gov) - Dec 4, 2012
P1/2, N=63, Recruiting, Sponsor: howard safran
- |||||||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative
New P2/3 trial, Metastases: AlloStim (clinicaltrials.gov) - Dec 2, 2012
P2/3, N=208, Not yet recruiting, Sponsor: Immunovative Therapies, Ltd.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer (clinicaltrials.gov) - Dec 2, 2012
P2, N=72, Completed, Sponsor: Eastern Cooperative Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Combination therapy, Metastases: A study to explore the effects of cetuximab alone or in combination with irinotecan in patients with an abnormal gene (KRAS) in their colon cancer cells. (EUDRACT) - Nov 27, 2012
P2, N=100, Ongoing, Sponsor: Australasian Gastro-Intestinal Trials Group, Sydney University